HAYWARD, Calif.--(BUSINESS WIRE)--Oct. 22, 2024--
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter ended September 30th, 2024.
Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 940081. Participants may also register for the call online using the following link: https://www.netroadshow.com/events/login?show=4818aee3&confId=72838. To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.
About Arcus Biosciences
Arcus Biosciences
is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for patients with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39, and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20241022900050/en/
Investor Inquiries
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
